welcome
CNBC

CNBC

Health

Health

FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca

CNBC
Summary
Nutrition label

87% Informative

Merck 's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus .

The approval gives doctors a new treatment option for the virus, which causes thousands of deaths among older Americans .

Complications from RSV are the leading cause of hospitalization among newborns.

The FDA paused testing of RSV shots in young children while it evaluates safety concerns.